Drug Development Must Be Patient-Centric; Adherence Schemes Must Follow
This article was originally published in The Pink Sheet Daily
Executive Summary
Global health systems are losing billions of dollars by not introducing schemes to tackle drug adherence, but are heading in the right direction with patient-centric drug development.
You may also be interested in...
Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Proposal To Improve Patient Information Attracts More EU Support
Pharma is relieved as an EU parliamentary committee approves revised information-to-patients proposals
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.